Zeta designs and develops tumor specific biomarkers using cutting edge technologies to uniquely select the immunogens for our famed MonoSpecific monoclonal Rabbit and Mouse antibodies. Zeta manufactures products at a FDA registered facility in California under stringent ISO 13485-2016 guidelines. Our Rabbit monoclonal array of products are curated to reproduce very specific and sensitive IHC results on any platforms or manually. We incorporate mostly recombinant technology for our antibody development apart from hybridomas. Zeta antibodies are target-validated for IHC.